Ekso Bionics Holdings, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 15 - Net Loss Per Share (Tables)

Note 15 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		*Three Months Ended*
		*March 31,*
		*2026*				*2025*
Numerator:
Net loss applicable to common stockholders		$	(6,885	)		$	(2,891	)
Adjustment for deemed dividend in connection with equity financings (, *)			(376	)			(226	)
Adjusted net loss used for basic and diluted calculation		$	(7,261	)		$	(3,117	)

Denominator:
Weighted-average number of common shares, basic and diluted			3,563				1,693

Net loss per common share:
Basic and diluted		$	(2.04	)		$	(1.84	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		*Three Months Ended*
		*March 31,*
		*2026*				*2025*
Options to purchase common stock			10				12
Restricted stock units			82				56
Convertible Series B Preferred Stock			712				—
B. Riley Promissory Note conversion option			243				—
Warrants for common stock			1,158				913
Shares held in abeyance			—				466
Total common stock equivalents			2,205				1,447